HONG KONG – Undeterred by the underperformance of peers on the Hong Kong Stock Exchange, Suzhou's Cstone Pharmaceuticals Co. Ltd. filed for an IPO on Monday, becoming the 16th biotech company to seek a listing in Hong Kong under the new rules. Proceeds will be used to advance its core asset, CS-1001, aiming to be one of the first PD-L1 antibodies approved in China. Read More
PERTH, Australia – Australian regenerative medicine company Mesoblast Ltd.'s allogeneic cell therapy candidate, MPC-150-IM, failed to meet the primary endpoint in a phase IIb trial in end-stage heart failure patients implanted with a left ventricular assist device (LVAD), but it delivered meaningful clinical results that may make it approvable. Read More
SHANGHAI – The verdict is in. The regulatory reforms that China kicked off in 2015 have opened the floodgates to an unprecedented number of early phase clinical trials being conducted in China. Read More
HONG KONG – Chinese biologics and biosimilars maker Bio-Thera Solutions Ltd. kicked off a phase III trial of its HER2 antibody-drug conjugate (ADC), BAT-8001, targeting HER2-positive metastatic cancer. Read More
A miniature eye patch delivering drugs directly into the eye for safer and more effective treatment of ocular diseases has been reported by researchers at Singapore's Nanyang Technological University in the Nov. 6, 2018, edition of Nature Communications. Read More
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, disclosed the publication of a circular containing a notice of its decision to hold an extraordinary general meeting of shareholders to vote on the necessary matters relating to the acquisition of Dublin-based Shire plc. Read More
